文献速递瓣膜外科

无支架Freestyle生物瓣衰败后瓣中瓣TAVR的中期结局

Midterm Outcomes for Valve-in-Valve Transcatheter Aortic Valve Replacement in the Failed Freestyle Bioprosthesis.
PubMed 文献 · Ann Thorac Surg · 2020-05-19

单中心回顾性研究纳入56例Freestyle无支架生物瓣衰败患者,采用自膨胀经导管瓣行ViV TAVR。器械成功率82%,6例需置入两个瓣膜,手术死亡3例(5%),3年生存率82%,提示该术式技术挑战大但中期结果可接受,且存在早期学习曲线。

要点

  • Freestyle瓣衰败以反流为主(77%),64%需紧急干预。
  • 自膨胀瓣ViV TAVR器械成功率82%,6例需双瓣置入。
  • 3年生存率82%,30天无中度以上瓣周反流。

核心结论

  • Freestyle无支架瓣行ViV TAVR技术挑战大,但中期结果良好,器械成功率与早期学习曲线相关。

主要发现

  • 平均年龄75±8岁,STS平均风险评分9%±8%。
  • Freestyle瓣衰败以反流为主(77%),36例(64%)因难治性急性心衰需紧急干预。
  • 器械成功率82%,6例(11%)需置入两个经导管瓣膜,手术死亡3例(5%)。
  • 30天随访无患者存在中度以上瓣周反流;30天和1年平均主动脉瓣压差分别为11±8和9±8 mm Hg。
  • 30天后存活患者3年生存率82%;后期患者器械成功率高于早期患者(P = .02)。

临床怎么用

  • 对于外科高危的Freestyle瓣衰败患者,ViV TAVR可采用自膨胀瓣实施,但需注意技术挑战和早期学习曲线。

局限性

  • 回顾性单中心设计,样本量56例,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is acceptable in patients at high risk for reoperation. Studies suggest that ViV TAVR in stentless valves may be technically more challenging. This study sought to evaluate midterm outcomes for ViV TAVR in the degenerative Freestyle ((Medtronic, Minneapolis, MN)) stentless bioprosthesis. METHODS: Between October 2014 and January 2019, 56 patients underwent ViV TAVR for a failed Freestyle valve at a single institution using a commercially available self-expanding transcatheter aortic valve. Patient baseline characteristics and clinical outcomes data were collected retrospectively. Valve Academic Research Consortium-2 definitions were applied. RESULTS: Mean patient age was 75 ± 8 years and The Society of Thoracic Surgeons mean risk score was 9% ± 8%. The predominant mode of Freestyle valve failure was regurgitation (77%), and 36 patients (64%) required urgent intervention for refractory acute heart failure. Device success using a self-expanding TAVR was 82%, with 6 cases (11%) requiring deployment of two transcatheter valves. There were 3 operative mortalities (5%). At 30-day follow-up, no patient had greater than moderate perivalvular regurgitation. Device success was higher in the later patients compared with patients done earlier (P = .02). Mean aortic valve gradients at 30 days and 1 year were 11 ± 8 and 9 ± 8 mm Hg, respectively. For patients alive beyond day 30, 3-year survival was 82%. CONCLUSIONS: Performing ViV TAVR in the Freestyle valve using a self-expanding transcatheter valve presents a technical challenge, but may be feasible with good midterm results. Procedural success is associated with an early hazard learning curve.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wai Sang SL, DeBruine N, Beute T, et al. Midterm Outcomes for Valve-in-Valve Transcatheter Aortic Valve Replacement in the Failed Freestyle Bioprosthesis. Ann Thorac Surg. 2020. PMID: 32442615. doi:10.1016/j.athoracsur.2020.03.116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。